Parkinson’s: the search for a cure (video, episode two)
Parkinson’s disease is the fastest growing brain disease in the world. This is partially attributable to the ageing population, yet it is becoming apparent that other factors, such as agricultural pesticides, heavy metals, and solvents, may also play a role in this. The challenge for the future is to find a medicine, as none have yet been found. Thankfully, plenty of research is being conducted on the disease. Within the UG, too, various scientists are busy researching Parkinson’s disease.
In this series, we are highlighting a number of researchers who are researching topics including the emergence, cause, identification, and inhibition of the disease from their own different perspectives. All of these researchers find it important to contribute to better understanding, and eventually finding a cure for, this disease.
Joining us in the second episode of this series are Prof. Amalia Dolga, Associate Professor of Molecular Pharmacology, and Prof. Arjan Kortholt, Associate Professor of Cell Biochemistry. With Parkinson’s disease, brain cells that produce the neurotransmitter dopamine die off. But what causes this? There is evidence to suggest that the problems start in the immune system in the brain. Dolga and Kortholt believe that microglia, immune cells in the brain, could play a role here. They recently received a €250,000 grant from Stichting Parkinson Fonds (the Dutch Parkinson’s fund) to research what goes wrong with the microglia. One problem, however, is that it is nearly impossible to retrieve brain cells from patients. Amalia Dolga has recently developed a new technique to cultivate brain cells from stem cells.
Both labs are also jointly researching the protein LRRK2 because it plays a part in the symptoms of many patients. Kortholt studies the effects of a LRRK2 inhibitor. Most inhibitors that are currently available also affect other organs, such as the kidneys. That causes serious side-effects, making them unsuitable as medicine. Kortholt has discovered inhibitors that, instead of fully inhibiting LRRK2's activity, halve it. These inhibitors do not seem to have any side-effects, which is a hopeful development in the search for a cure.
Last modified: | 05 April 2023 12.01 p.m. |
More news
-
17 July 2024
Veni-grants for ten researchers in Groningen
The Dutch Research Council (NWO) has awarded a Veni grant of up to €320,000 each to ten researchers of the University of Groningen and the UMCG. The Veni grants are designed for outstanding researchers who have recently gained a PhD.
-
15 July 2024
Funding for RUG researchers from National Growth Fund programme Circular Plastics NL
For research on making plastics circular, Professors Patrizio Raffa and Katja Loos together receive about 1.2 million euros from the National Growth Fund programme Circular Plastics NL.
-
09 July 2024
NWO Open Technology funding for improving quality 3D printing technology
Dr. Liangliang Cheng receives a NWO OPT grant of EUR 950,000 for research on safer application of metals in 3D printing technology.